

SEE **GA** DIFFERENTLY

**GEOGRAPHIC ATROPHY:**

# Imaging Guide for Early Detection and Monitoring

# Taking a closer look at geographic atrophy

In addition to taking a clinical history and examination, multi-modal imaging may help with early detection, diagnosis, and monitoring of the progression of age-related macular degeneration (AMD) to geographic atrophy (GA).<sup>1,2</sup>

The following imaging modalities may be used to detect and monitor progression of AMD to GA: optical coherence tomography (OCT), fundus autofluorescence (FAF), and colour fundus photography (CFP).<sup>1</sup>

Timely detection and subsequent monitoring of AMD in patients may be an important clinical consideration.<sup>2</sup> This guide focuses on intermediate and late AMD, which are more likely to be symptomatic than earlier stages of the disease.<sup>3</sup>



## DIAGNOSTIC HALLMARKS

### Early AMD

Multiple small (<math><63\ \mu\text{m}</math>) and few intermediate (<math>63\text{-}124\ \mu\text{m}</math>) drusen, or retinal pigment epithelium (RPE) abnormalities.<sup>4</sup>

### Intermediate AMD

Extensive intermediate drusen (<math>63\text{-}124\ \mu\text{m}</math>) or more than 1 large drusen (<math>\geq 125\ \mu\text{m}</math>). May also be accompanied by degenerative changes in the choriocapillaris, RPE, and photoreceptors.<sup>2,4,5</sup>

### Advanced AMD (GA)

Progressive atrophy of choriocapillaris, RPE, and photoreceptors; new and/or growing atrophic lesions.<sup>2,6,7</sup>

## Optical coherence tomography (OCT)

OCT is the standard of care for assessing patients in their initial AMD diagnosis.<sup>8,9</sup>




Image courtesy of Dr. Arshad Khanani

### Intermediate AMD

1. Intermediate (<math>63\text{-}124\ \mu\text{m}</math>) and large (<math>\geq 125\ \mu\text{m}</math>) drusen<sup>4</sup>
2. Hyperreflective foci correspond to disruption of the RPE<sup>10</sup>
3. Photoreceptor degradation<sup>8</sup>

The transition from intermediate AMD to GA may be clinically important; timely recognition of new imaging signs may be helpful in informing the clinical management of patients.<sup>11</sup>




Image courtesy of Dr. Arshad Khanani

### Advanced AMD (GA)

1. Choroidal hypertransmission<sup>4</sup>
2. RPE, photoreceptor, and choriocapillaris layer loss<sup>9</sup>

## Fundus autofluorescence (FAF)

FAF may be used to diagnose and monitor disease progression in GA; it measures the full retinal area.<sup>12</sup> FAF may be a helpful modality in patient education.




Image courtesy of Dr. Arshad Khanani

### Intermediate AMD

1. Reticular pseudodrusen appearing as multiple, clustered, regularly networked, round areas of low-contrast hypoautofluorescence and may be prognostic of advancing GA<sup>12,13</sup>




Image courtesy of Dr. David Lally

### Advanced AMD (GA)

1. An area of hypoautofluorescence with a sharply demarcated border indicative of atrophic lesions<sup>4</sup>
2. Abnormal patterns of hyperautofluorescence surrounding atrophic lesions can indicate excessive lipofuscin accumulation that may reflect cellular dysfunction and may be prognostic of GA progression<sup>4</sup>

## Colour fundus photography (CFP)

Can be used to establish a baseline and detect pigmentary changes throughout disease progression.<sup>1</sup>




Image courtesy of Dr. Arshad Khanani

### Intermediate AMD

1. Increase in number of intermediate (63-124 μm) drusen<sup>4</sup>
2. Areas of pigmentary change associated with RPE abnormalities<sup>14</sup>




Image courtesy of Dr. Arshad Khanani

### Advanced AMD (GA)

1. GA lesion border is sharply demarcated with increased choroidal vessel visibility<sup>1</sup>



**TIP:** A red-free filter on CFP can help to delineate retinal abnormalities.<sup>15</sup>

## iRORA vs cRORA

Incomplete RPE and outer retinal atrophy (iRORA), also known as nascent GA in the absence of choroidal neovascularisation, represents an earlier phase of disease progression before advancing to complete RPE and outer retinal atrophy (cRORA).<sup>8</sup>




Image courtesy of Dr. Carl Danzig

### iRORA<sup>16</sup>

1. Some hypertransmission present in the choroid, but it is discontinuous
2. A corresponding zone of attenuation and disruption of RPE with persistence of basal laminar deposits
3. Photoreceptor degeneration

cRORA is a more advanced stage of atrophy.<sup>8</sup>




Image courtesy of Dr. Arshad Khanani

### cRORA<sup>8,\*</sup>

1. Area of choroidal hypertransmission  $\geq 250 \mu\text{m}$
2. Zone of attenuation/disruption of RPE  $\geq 250 \mu\text{m}$
3. Evidence of overlying photoreceptor degeneration, which includes ONL thinning, ELM loss, and EZ/IZ loss

\*Absence of scrolled RPE or other signs of an RPE tear.



**TIP:** Optimisation of instrumentation can minimise artefacts and improve the quality of imaging.<sup>17</sup> Work with your imaging partner to configure your instrument to your needs and specifications.

## Lesion characteristics can predict rate of progression

Hyperautofluorescent FAF patterns can be predictive of the rate of GA progression. Rate of progression is slowest with no hyperautofluorescence or a focal pattern, and highest with banded or diffuse patterns. Eyes with diffuse-trickling patterns may also progress relatively quickly.<sup>4</sup>

### Banded pattern




Image courtesy of Dr. Arshad Khanani

### Diffuse pattern




Image courtesy of Dr. Arshad Khanani

### Diffuse-trickling pattern




Image courtesy of Dr. Carl Danzig

**Clinical imaging may be helpful in the early detection of geographic atrophy and minimising the impact of the disease.<sup>11</sup>**

## References:

1. Holz FG, Sadda SR, Staurengi G, et al. Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus Meetings. *Ophthalmology*. 2017;124(4):464-478.
2. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern(R). *Ophthalmology*. 2020;127(1):P1-P65.
3. Stahl A. The Diagnosis and Treatment of Age-Related Macular Degeneration. *Dtsch Arztebl Int*. 2020;117(29-30):513-520.
4. Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. *Ophthalmology*. 2018;125(3):369-390.
5. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. *Nat Rev Dis Primers*. 2021;7(1):31.
6. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. *J Clin Invest*. 2014;124(4):1430-1438.
7. Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. *Retina*. 2017;37(5):819-835.
8. Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of Atrophy Report 3 [published correction appears in *Ophthalmology*. 2019;126(1):177]. *Ophthalmology*. 2018;125(4):537-548.
9. Elsharkawy M, Elrazzaz M, Ghazal M, et al. Role of optical coherence tomography imaging in predicting progression of age-related macular disease: a survey. *Diagnostics (Basel)*. 2021;11(12):2313.
10. Fragiotta S, Abdolrahimzadeh S, Dolz-Marco R, Sakurada Y, Gal-Or O, Scuderi G. Significance of hyperreflective foci as an optical coherence tomography biomarker in retinal diseases: characterization and clinical implications. *J Ophthalmol*. 2021;2021:6096017.
11. Regillo CD, Nijm LM, Shechtman DL, et al. Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel. *Clin Ophthalmol*. 2024;18:325-335.
12. Sadda SR, Chakravarthy U, Birch DG, et al. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. *Retina*. 2016;36(10):1806-1822.
13. Xu L, Blonska AM, Pumariega NM, et al. Reticular macular disease is associated with multilobular geographic atrophy in age-related macular degeneration. *Retina*. 2013;33(9):1850-1862.
14. Heesterbeek TJ, Lores-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol Opt*. 2020;40(2):140-170.
15. Ly A, Nivison-Smith L, Assaad N, Kalloniatis M. Fundus autofluorescence in age-related macular degeneration. *Optom Vis Sci*. 2017;94(2):246-259.
16. Guymer RH, Rosenfeld PJ, Curcio CA, et al. Incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: classification of atrophy meeting report 4. *Ophthalmology*. 2020;127(3):394-409.
17. De Pretto LR, Moulton EM, Alibhai AY, et al. Controlling for artifacts in widefield optical coherence tomography angiography measurements of non-perfusion area. *Sci Rep*. 2019;9(1):1-5.

SEE GA DIFFERENTLY

